Progression of stage T1 bladder tumors after intravesical bacillus Calmette-Guerin

J Urol. 1991 Jan;145(1):40-3; discussion 43-4. doi: 10.1016/s0022-5347(17)38242-3.

Abstract

Of 221 patients with superficial bladder tumors (stages Ta, Tis and T1) treated by transurethral resection and an initial 6-week course of intravesical bacillus Calmette-Guerin (BCG) 195 were evaluated after 3 months for local response. Of these patients 17 (8.7%) had a stage T1 tumor, of whom 14 (82%) subsequently had muscle invasion (7), uncontrolled local disease (6) or metastasis (1). The median interval to progression was 8.4 months, which was significantly (p = 0.0001) less than among the other 178 patients with a nonstage T1 lesion or no tumor found at 3 months, of whom 44 (25%) had progression (median more than 5 years). These data suggest that patients with stage T1 tumor 3 months after BCG therapy require additional therapy other than simple tumor resection and meticulous followup.

MeSH terms

  • BCG Vaccine / therapeutic use*
  • Combined Modality Therapy
  • Follow-Up Studies
  • Humans
  • Multivariate Analysis
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local / epidemiology
  • Neoplasm Staging
  • Postoperative Care
  • Prognosis
  • Proportional Hazards Models
  • Time Factors
  • Urinary Bladder / surgery
  • Urinary Bladder Neoplasms / epidemiology
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / therapy*

Substances

  • BCG Vaccine